PharmaLectures.com

Courses › Regulatory affairs by region › European Union: Biosimilars at the EMA, comparability, extrapolation and the pathway

European Union: Biosimilars at the EMA, comparability, extrapolation and the pathway

Your biosimilar dossier answers the European Medicines Agency before it asks.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

The Committee for Medicinal Products for Human Use sends your biosimilar a list of questions, and the first asks why the reference product was characterized after testing began. The clock stops, your team repeats analytical work, and a competitor reaches the market first.

What changes after this course

Your team builds the comparability package in the order guideline CHMP/437/04 Rev 1 expects, and the answers sit in the dossier. You hold a certificate for every learner and a training record for each person, ready for any audit.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

A deficiency question arrives about your analytical similarity margins, and your regulatory affairs manager answers from the guideline, not from memory. They apply the step-wise approach in CHMP/437/04 Rev 1 to your quality, non-clinical and clinical data in the right order. The Committee for Medicinal Products for Human Use finds the answer to its first concern already in the dossier.

Business development decides on an extra indication in one meeting. The lead checks mechanism of action and immunogenicity against the extrapolation rules, then either removes the trial from the budget or tells the team what data the claim still needs. In vivo animal studies leave the plan when functional in vitro assays already show the activity.

Quality assurance reads a draft Common Technical Document and knows what belongs where. Comparability reports land in Module 3, non-clinical reports in Module 4, clinical evidence in Module 5. The totality of evidence reads as one argument under Directive 2001/83/EC Article 10(4), so assessors stop hunting through sections.

After approval, your pharmacovigilance work holds up. The risk management plan follows Good Pharmacovigilance Practices Module V, and the periodic safety update report dates sit in one calendar with a named owner. When an inspector asks how you monitor immunogenicity, the answer is already written.

Who needs this training

  • Regulatory Affairs Manager

    Holds a deficiency letter on analytical similarity margins and needs the equivalence reasoning written before the response deadline, not after days of searching through guidelines.

  • Quality Assurance Specialist

    Reviews a draft Common Technical Document the week before filing and spots that the non-clinical overview in Module 2 does not match the study reports in Module 4.

  • Business Development Lead

    Sits in a portfolio meeting where someone asks whether a secondary indication needs its own trial, and answers from the extrapolation rules instead of promising to check.

  • Pharmacovigilance Lead

    Drafts the risk management plan for a new biosimilar and must show the immunogenicity monitoring an inspector will ask about after approval.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Apply Directive 2001/83/EC Article 10(4) to decide the filing pathway for a biosimilar before dossier work starts.
  2. Defend an analytical similarity margin with an equivalence testing argument written for an assessor.
  3. Justify skipping an in vivo animal study with functional in vitro assay data.
  4. Select the most sensitive patient population for a comparative clinical efficacy trial and state the reason.
  5. Decide whether an indication can be extrapolated by checking mechanism of action and immunogenicity.
  6. Place comparability reports in Common Technical Document Modules 3, 4 and 5 where assessors expect them.
  7. Draft a risk management plan outline that follows Good Pharmacovigilance Practices Module V.

What the company gets

  • Your biosimilar dossier answers the first round of assessor questions before they are asked, so there is less reason to stop the clock.
  • Every extrapolated indication in your portfolio carries a written justification that an assessor can read in minutes.
  • Teams stop repeating analytical work, because the reference product is characterized and the quality attributes are settled before testing begins.
  • Quality assurance holds one training record per person and a certificate per learner, ready to show an inspector or a licensing partner.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Apply Directive 2001/83/EC Article 10(4) to pick your pathway

    • Why Article 10(4) decides which data you owe, before anyone drafts a single section.
    • How to tell in one meeting whether your product belongs on the centralised procedure.
    • What to do when someone asks which reference medicinal product your whole package rests on.
  2. 2Prove biosimilarity with the totality of evidence approach

    • How to present quality, safety and efficacy data as one argument that a reviewer can follow.
    • Why highly similar is the standard you prove, and identical is the standard you stop chasing.
    • The gap in a comparability story that makes assessors ask for a bigger clinical study.
  3. 3Run the step-wise approach in guideline CHMP/437/04 Rev 1

    • How to order your work the way CHMP/437/04 Rev 1 expects, so no step is repeated.
    • Why quality data come first in the step-wise approach and how they shrink what the clinic must show.
    • When to settle the critical quality attributes, and what that does to the rest of your testing plan.
  4. 4Structure analytical, non-clinical and clinical comparability

    • How to split the evidence between analytical, non-clinical and clinical sections without gaps.
    • When a non-clinical study closes a doubt the analytics leave open, and when it adds nothing.
    • The clinical design choice that lets a trial detect a real difference instead of hiding it.
  5. 5Justify analytical differences with equivalence testing margins

    • How to set an equivalence margin and write the reasoning that defends it at assessment.
    • What to do when a sensitive method shows a small difference in a quality attribute.
    • The argument that shows a difference does not reach the patient, so the question closes.
  6. 6Waive in vivo animal studies with functional in vitro assays

    • Why a set of functional in vitro assays can replace an animal study in your plan.
    • When the Agency still asks for in vivo data, and how to spot it before you file.
    • How to write the justification for skipping an animal study so a reviewer accepts it.
  7. 7Select the most sensitive patient population for efficacy trials

    • Why pharmacokinetic and pharmacodynamic data open the clinical step and what they must show.
    • How to pick the patient population most sensitive to a difference, and defend the pick.
    • The safety data a comparative trial must collect to catch a relevant clinical difference.
  8. 8Extrapolate indications without running new clinical trials

    • How to claim an indication you never tested in the clinic and have the claim hold at review.
    • What the Agency expects your comparability data to show before one indication can carry another.
    • Why extrapolation is argued indication by indication, and how to write each argument.
  9. 9Match mechanism of action and immunogenicity for new indications

    • How to show that the same mechanism of action carries over to the new indication.
    • When a different disease mechanism sinks the extrapolation, so you drop it before filing.
    • The immunogenicity evidence assessors want before they accept a population you did not study.
  10. 10Draft Common Technical Document Modules 3, 4 and 5 for assessors

    • How to place comparability reports in Module 3 where the quality assessor looks first.
    • Where the non-clinical reports go in Module 4 so the overview and the studies agree.
    • How to lay out Module 5 so the clinical reviewer finds the pivotal evidence on the first pass.
  11. 11Submit periodic safety update reports and risk management plans

    • How to build a risk management plan that follows Good Pharmacovigilance Practices Module V.
    • When periodic safety update reports fall due, and who in your company owns each date.
    • What an inspector asks your pharmacovigilance system after approval, and the answers to have ready.
  12. 12Prevent rejections caused by poor reference characterization

    • Why late reference product characterization draws questions, and how to settle it before testing.
    • How to catch a statistical analysis error in your own file before an assessor does.
    • The extrapolation slip that leaves an indication off your label, and how to avoid it.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team